Patents Represented by Attorney Gerald V. Dahling
  • Patent number: 5534488
    Abstract: The present invention is directed to an insulin formulation comprising a suspension of Ultralente crystals and a total formulation zinc concentration of between about 0.5 milligrams to about 20 milligrams per 100 units of insulin. Greater than fifty percent of the total zinc in the formulation resides in the soluble fraction, rather than in complex with the insulin. This insulin formulation generally has a pH from between about 6.0 to about 7.4. In addition, the insulin formulation of the present invention does not contain other proteins like protamine. This zinc-modified formulation displays characteristics of a very long lasting human insulin product.
    Type: Grant
    Filed: August 13, 1993
    Date of Patent: July 9, 1996
    Assignee: Eli Lilly and Company
    Inventor: James A. Hoffmann
  • Patent number: 5500346
    Abstract: Monoclonal antibodies which react with the human influx peptide transporter are provided. The human influx peptide transporter-reactive antibodies are useful in the purification of influx peptide transporter and in immunoassays to identify agents taken up into the cell by the human influx peptide transporter mechanism. The monoclonal antibodies are also useful for the detection and treatment of carcinomas derived from the gastrointestinal tract and pancreatic duct.
    Type: Grant
    Filed: June 29, 1993
    Date of Patent: March 19, 1996
    Assignee: Eli Lilly and Company
    Inventors: Stuart W. Bright, Anne H. Dantzig, Linda B. Tabas, J. Richard Sportsman
  • Patent number: 5488053
    Abstract: The present invention provides pentacyclic pyrido[3,4-b]indoles having useful central nervous system activity.
    Type: Grant
    Filed: March 11, 1994
    Date of Patent: January 30, 1996
    Assignee: Eli Lilly and Company
    Inventors: James E. Audia, James J. Droste, Deborah A. Evrard
  • Patent number: 5474978
    Abstract: The present invention discloses a human insulin analog hexamer complex and formulations. More specifically, the present invention relates to various parenteral formulations, which comprise: human insulin analogs in a hexamer conformation, zinc ions, and at least three molecules of a phenolic derivative selected from the group consisting of m-cresol, phenol, or a mixture of m-cresol and phenol. The formulation provides a rapid onset of action.
    Type: Grant
    Filed: June 16, 1994
    Date of Patent: December 12, 1995
    Assignee: Eli Lilly and Company
    Inventors: Diane L. Bakaysa, David N. Brems, Bruce H. Frank, Henry A. Havel, Allen H. Pekar
  • Patent number: 5468757
    Abstract: Selected acid functional 6-azaindole type derivatives effective as thromboxane synthase inhibitors having the formula (II): ##STR1## where n is an integer from zero to 3, m is an integer from zero to 2, R.sub.1 and R.sub.2 are monovalent radicals, --(L.sub.a)-- is a linking group of 4 to 8 chain atoms, and A is an acidic group.
    Type: Grant
    Filed: January 31, 1994
    Date of Patent: November 21, 1995
    Assignee: Eli Lilly and Company
    Inventors: Joseph A. Jakubowski, Alan D. Palkowitz, Sandra K. Sigmund
  • Patent number: 5468632
    Abstract: The present invention provides isolated DNA compounds and recombinant DNA cloning and expression vectors that encode PNB esterase from Bacillus subtilis. The invention also provides host cells transformed with these vectors and a method for production of the PNB esterase by recombinant DNA techniques.
    Type: Grant
    Filed: September 22, 1993
    Date of Patent: November 21, 1995
    Assignee: Eli Lilly and Company
    Inventors: Cathleen A. Cantwell, Roland L. Hodges, Derek McGilvray, Stephen W. Queener, James R. Swartling, Joseph M. Zock
  • Patent number: 5468773
    Abstract: Wortmannin and certain of its analogs are inhibitors of bone loss/bone resorption and cartilage degradation.
    Type: Grant
    Filed: June 13, 1994
    Date of Patent: November 21, 1995
    Assignee: Eli Lilly and Company
    Inventors: Jeffrey A. Dodge, Masahiko Sato
  • Patent number: 5466810
    Abstract: A group of 2-amino-3-aroyl-benzo[.beta.]thiophenes are prepared by treating an aldehyde with an anion of dimethylamino thioformamide, cyclizing the .alpha.-hydroxy thioamide, and subsequently acylating the benzo[.beta.]thiophene to yield the 2-amino-3-aryl derivative. These compounds may be treated with suitable phenyl Grignard reagents, and after deprotection, yield 6-hydroxy-2-(4-hydroxyphenyl)-3-[4-(2-piperidinoethoxy)benzoyl]benzo[.beta .]thiophene.
    Type: Grant
    Filed: June 10, 1994
    Date of Patent: November 14, 1995
    Assignee: Eli Lilly and Company
    Inventor: Alexander G. Godfrey
  • Patent number: 5462937
    Abstract: Methods of inhibiting vascular smooth muscle cell proliferation and restinosis are disclosed comprising administering to a human or other mammal in need of treatment an effective amount of a compound having the formula ##STR1## wherein R.sub.1 and R.sub.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sub.2 is ##STR3## and R.sub.4 is hydrogen or --OR.sub.1, and pharmaceutically acceptable salts and solvates thereof.
    Type: Grant
    Filed: April 14, 1995
    Date of Patent: October 31, 1995
    Assignee: Eli Lilly and Company
    Inventors: George J. Cullinan, Jai P. Singh, Dan L. Wood
  • Patent number: 5462949
    Abstract: A method of inhibiting fertility in women comprising administering to a female human an effective amount of a compound having the formula ##STR1## and pharmaceutically acceptable salts and solvates thereof.
    Type: Grant
    Filed: December 21, 1993
    Date of Patent: October 31, 1995
    Assignee: Eli Lilly and Company
    Inventors: Charles D. Jones, Frank C. Tinsley
  • Patent number: 5460953
    Abstract: A method for the recombinant production of forms of human protein C with higher activity is described. These forms differ from native protein C in their increased amidolytic and functional activities and novel carbohydrate structures. DNA compounds, vectors, and transformants useful in the method are also disclosed.
    Type: Grant
    Filed: September 9, 1993
    Date of Patent: October 24, 1995
    Assignee: Eli Lilly and Company
    Inventors: Bruce E. Gerlitz, Brian W. Grinnell
  • Patent number: 5461065
    Abstract: A method of inhibiting endometriosis comprising administering to a human in need of treatment an effective amount of a compound having the formula ##STR1## Wherein R.sup.1 and R.sup.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl;R.sup.2 is selected from the group consisting of pyrrolidine and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
    Type: Grant
    Filed: October 15, 1993
    Date of Patent: October 24, 1995
    Assignee: Eli Lilly and Company
    Inventors: Larry J. Black, George J. Cullinan, Michael W. Draper, Charles D. Jones, David E. Seyler
  • Patent number: 5461031
    Abstract: The present invention discloses various parenteral pharmaceutical formulations, which comprise: a monomeric insulin analog, zinc, protamine, and phenolic derivative. The analog formulations provide a prolonged duration of action. A process for preparing insulin analog-protamine formulations is also described.
    Type: Grant
    Filed: June 16, 1994
    Date of Patent: October 24, 1995
    Assignee: Eli Lilly and Company
    Inventor: Michael R. De Felippis
  • Patent number: 5461154
    Abstract: The present invention provides novel HIV protease inhibitors, pharmaceutical formulations containing those compounds and methods of treating and/or preventing HIV infection and/or AIDS.
    Type: Grant
    Filed: February 2, 1994
    Date of Patent: October 24, 1995
    Assignee: Eli Lilly and Company
    Inventors: Louis N. Jungheim, Timothy A. Shepherd
  • Patent number: 5461064
    Abstract: A method of inhibiting atrophy of the skin or vagina comprising administering to a human in need thereof an effective amount of a compound having the formula ##STR1## wherein R.sup.1 and R.sup.3 are independently hydrogen, ##STR2## wherein Ar is optionally substituted phenyl; R.sup.2 is selected from the group consisting of pyrrolidine, hexamethyleneamino, and piperidino; or a pharmaceutically acceptable salt of solvate thereof.
    Type: Grant
    Filed: December 21, 1993
    Date of Patent: October 24, 1995
    Assignee: Eli Lilly and Company
    Inventor: George J. Cullinan
  • Patent number: 5457113
    Abstract: Methods of inhibiting vascular smooth muscle cell proliferation and vascular restinosis comprising administering to a human or other mammal in need of treatment an effective amount of a compound having the formula ##STR1## wherein R.sub.1 and R.sub.3 are independently hydrogen, --CH.sub.3, ##STR2## wherein Ar is optionally substituted phenyl; R.sub.2 is ##STR3## R.sub.4 is hydrogen or --OR.sub.1, and pharmaceutically acceptable salts and solvates thereof.
    Type: Grant
    Filed: October 15, 1993
    Date of Patent: October 10, 1995
    Assignee: Eli Lilly and Company
    Inventors: George J. Cullinan, Jai P. Singh, Dan L. Wood
  • Patent number: 5457121
    Abstract: This invention provides ring-substituted cis-hexahydro-5-(1,2,3,4-tetrahydro-2-naphthalenyl)pyrrolo<3,4-c>pyrroles which are selective inhibitors of serotonin reuptake.
    Type: Grant
    Filed: September 2, 1994
    Date of Patent: October 10, 1995
    Assignee: Eli Lilly and Company
    Inventors: John M. Schaus, Robert D. Titus
  • Patent number: 5457117
    Abstract: The current invention provides a method useful for inhibiting the loss of bone using 6-hydroxy-2-(4-hydroxyphenyl)-benzo(B)thien-3-yl-4[2-(piperidin-1-ethoxyph enol]methanone hydrochloride.
    Type: Grant
    Filed: October 26, 1994
    Date of Patent: October 10, 1995
    Assignee: Eli Lilly and Company
    Inventors: Larry J. Black, George J. Cullinan
  • Patent number: 5457101
    Abstract: The compound 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of certain gastrointestinal disorders.
    Type: Grant
    Filed: June 3, 1994
    Date of Patent: October 10, 1995
    Assignee: Eli Lilly and Company
    Inventors: Beverley Greenwood, David L. G. Nelson
  • Patent number: 5457116
    Abstract: A method of inhibiting uterine fibrosis comprising administering to a human or other mammal in need of treatment an effective amount of a compound having the formula ##STR1## Wherein R.sup.1 and R.sup.3 are independently hydrogen, ##STR2## wherein Ar is optionally substituted phenyl; wherein R.sup.2 is selected from the group consisting of pyrrolidino and piperidino, a pharmaceutically acceptable salt or solvate thereof.
    Type: Grant
    Filed: October 15, 1993
    Date of Patent: October 10, 1995
    Assignee: Eli Lilly and Company
    Inventors: Larry J. Black, George J. Cullinan, Michael W. Draper, Charles D. Jones, David E. Seyler